Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986326
- Development stage
- Phase 1
- Lead developer
- NewCo
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
BMS-986326 is a novel fusion protein therapeutic developed by Bristol Myers Squibb. It targets the interleukin-2 receptor alpha subunit (CD25), acting as an antagonist to modulate immune responses. The drug is designed for the treatment of immune-mediated diseases, with primary indications including atopic dermatitis and various forms of lupus (discoid lupus erythematosus, subacute cutaneous lupus erythematosus, systemic lupus erythematosus). Mechanistically, BMS-986326 inhibits signaling through the interleukin-2 receptor by binding to both IL-2 and CD25 components, thereby modulating T cell activity implicated in autoimmune and inflammatory conditions. It is administered via intravenous or subcutaneous routes and is currently undergoing Phase 1 clinical trials[1][2][9].
- Other names
- Multiple Ascending Dose SC
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)
Beyond the preview
Go deeper on BMS-986326.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986326.